For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens. Zacks Premium includes access to the Zacks Style Scores as well. What are the Zacks Style Score ...

Investors likely felt that with a compelling new product on the market, the company should have posted more meaningful growth. The stock of highly specialized healthcare company DexCom (DXCM -1.88%) wasn't the picture of health on Friday. It lost nearly 2% of its value in that day's trading session, on the back of an earnings release that raised investor concerns about slowing sales growth. The S&P 500 index outperformed the stock, and that's not saying much, as it essentially ended the day flat over Thursd ...

DexCom, Inc. DXCM reported better-than-expected third-quarter results on Thursday. DexCom reported quarterly earnings of 45 cents per share, which beat the analyst consensus estimate of 43 cents. Quarterly revenue came in at $994.2 million which beat the analyst consensus estimate of $990.71 million and is an increase over sales of $975 million from the same period last year.DexCom also announced Teri Lawver, executive vice president and chief commercial officer, will retire at the end of the year. Lawver w ...

DexCom, Inc. (DXCM) reported third-quarter 2024 adjusted earnings per share (EPS) of 45 cents, which beat the Zacks Consensus Estimate of 43 cents by 4.7%. The company had reported earnings of 50 cents per share in the prior-year quarter. DXCM registered GAAP net income per share of 34 cents, up from the year-ago quarter's figure of 29 cents. Revenue Details of Dexcom Total revenues grew 2% (3% on an organic basis) to $994.2 billion year over year, beating the Zacks Consensus Estimate by 0.3%. The revenue g ...

My last article about DexCom, Inc. (NASDAQ: DXCM ) was published almost one and a half years ago and similar to my previous articles about Dexcom, I was bearish about the stock. And while there might be stocks, I am rather bearish about, IMy analysis is focused on high-quality companies, that can outperform the market over the long-run due to a competitive advantage (economic moat) and high levels of defensibility. Focused on European and North American companies, but without constraints regarding market ca ...

DexCom, Inc. (NASDAQ:DXCM) Q3 2024 Earnings Call Transcript October 24, 2024 4:30 PM ET Company Participants Sean Christensen - VP, Finance and IR Kevin Sayer - President and CEO Jereme Sylvain - CFO Conference Call Participants Danielle Antalffy - UBS Larry Biegelsen - Wells Fargo Matt Taylor - Jefferies Jeff Johnson - Baird Robbie Marcus - JPMorgan Joanne Wuensch - Citibank Michael Polark - Wolfe Research Mathew Blackman - Stifel Travis Steed - Bank of America Marie Thibault - BTIG Matthew O'Brien - Piper ...

DexCom (DXCM) reported $994.2 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 2%. EPS of $0.45 for the same period compares to $0.50 a year ago. The reported revenue compares to the Zacks Consensus Estimate of $991.55 million, representing a surprise of +0.27%. The company delivered an EPS surprise of +4.65%, with the consensus EPS estimate being $0.43. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and h ...

DexCom (DXCM) came out with quarterly earnings of $0.45 per share, beating the Zacks Consensus Estimate of $0.43 per share. This compares to earnings of $0.50 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of 4.65%. A quarter ago, it was expected that this medical device company would post earnings of $0.39 per share when it actually produced earnings of $0.43, delivering a surprise of 10.26%. Over the last four quarters, the co ...

| --- | --- | --- | --- | |-----------------|-------|----------|-------| | | | | | | | | | | | Dexcom | | | | | Dexcom earnings | | ny faces | | | Q3 2024 | | Nasdag | | | | | | | | --- | --- | |----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

Table of Contents DEXCOM, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-51222 (Exact name of registrant as specified in its charter) Delaware 33-0857544 (State or other jurisd ...